Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
History
Unity Biotechnology was founded in 2011 by Ned David, Robert Nelsen, and Eric Denovo. The company had its initial public offering in 2019 and is headquartered in Brisbane, California.
Mission
Our mission is to extend healthy human lifespan by treating the underlying causes of aging, allowing us to avoid age-related illnesses and maintain physical and cognitive functions for longer.
Vision
Our vision is to redefine aging to be more like a chronic and manageable condition, where people can live healthier, longer, and with higher quality of life.
